PALO ALTO, Calif., June 25 — Cell Biosciences, Inc., a

provider of ultrasensitive protein detection and characterization systems

to life science researchers, today announced three important additions to

its management team.

Tim Harkness was named President and Chief Executive Officer. From 1998

through 2007, Mr. Harkness was the Chief Financial Officer for Molecular

Devices Corporation where he helped build the company into a global leader

in life science research tools with over $185 million in revenue before

successfully selling the company in 2007. Mr. Harkness brings deep

knowledge of worldwide life sciences markets, and is expected to lead the

transformation of Cell Biosciences into a mature commercial operation.

Richard Lussier was named Vice President, Sales and International

Operations. Mr. Lussier has more than 20 years experience in life science

sales and commercial operations, including 13 years in the Applera

businesses Applied Biosystems and Celera Genomics. During his tenure at

Applera, he served as President and General Manager of their Japanese

subsidiary for five years. More recently, Mr. Lussier established the

worldwide sales, service, and support organization for Solexa Inc., now

part of Illumina Inc.

Also announced was the appointment of Walter Ausserer, Ph.D. as Vice

President, Marketing. Dr. Ausserer has more than 15 years experience in the

development, sales, and marketing of bioanalytical instrumentation. Most

recently, he directed product development at Axela Biosensors, a developer

of label-free protein characterization systems. Dr. Ausserer previously

held senior product development and marketing positions at Caliper Life

Sciences and Dionex Corporation.

“The Cell Biosciences team has developed a truly revolutionary

technology for protein characterization that I believe has the potential to

significantly impact many areas of biological research,” said Mr. Harkness.

“I am impressed by the tremendous potential of the Cell Biosciences team

and technology, and am very excited about the opportunity to lead the

company.”

The management team appointments come on the heels of multiple recent

placements of the Firefly(TM) 3000 system, Cell Bioscience’s flagship

product for ultrasensitive detection and characterization of proteins in

extremely small biological samples. Cell Biosciences began accepting orders

for the Firefly 3000 system in late 2007 as part of an early technology

access program for leading cell signaling and translational medicine

researchers. Participants in the program receive early access to the

Firefly 3000 system, which provides unprecedented levels of sensitivity for

the analysis of precious samples, such as tissue biopsies, fine-needle

tumor aspirates, and stem cells.

To fuel its commercial expansion, the company closed a Series B

financing round of $27 million in late 2006, with participation from the

Wellcome Trust, Domain Associates, Latterell Venture Partners, Novo

Ventures, Posco BioVentures, Mitsui & Co. Venture Partners, RBC Capital

Partners and The Vertical Group.

About Cell Biosciences

Cell Biosciences is a private life sciences company focused on

nano-proteomics. We are developing instrumentation systems to enable the

detection of specific proteins in extremely small biological samples. The

company’s lead product, the Firefly 3000, is a capillary-based nanofluidic

immunoassay platform designed for ultrasensitive detection and

characterization of proteins. Cell Biosciences is located in Palo Alto, CA.

http://www.cellbiosciences.com